← All trials
NCT00127855
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2003
- Primary completion
- Feb 1, 2004
- Completion date
- Aug 1, 2004
- First posted
- —
- Last posted
- —
- Enrollment
- 409
- Arms / groups
- 5 / —
- Source
- AACT · pre-existing
Sponsors
- GlaxoSmithKlineLead sponsor
- GlaxoSmithKlineStudy director
Drugs studied
- haemophilus influenzae type b-neisseria meningitidis serogroups c and y-tetanus-toxoid conjugate vaccine
- pneumococcal 13-valent conjugate vaccine
- pneumococcal 13-valent conjugate vaccine
- polyribosyl ribitol phosphate
- polyribosyl ribitol phosphate
- glyco-conjugate neisseria meningitidis serogroup c vaccine
- Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine
- Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine
- meningococcal (groups A, C, Y, W) tetanus toxoid conjugate vaccine
- meningococcal (groups A, C, Y, W) tetanus toxoid conjugate vaccine
- haemophilus influenzae type b conjugate vaccine
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.